EASD 2026: Roche’s enicepatide shows 22.7% placebo-adjusted weight loss at 48 weeks
Key opinion leaders interviewed by GlobalData viewed enicepatide's dual-receptor mechanism as a significant advancement over single-target GIP agonism.
The post EASD 2026: Roche’s enicepatide shows 22.7% placebo-adjusted weight loss at 48 weeks appeared first on Clinical Trials Arena .